Loading
If Enhertu produces complete responses in two-thirds of patients before surgery, a trial should test whether some need no chemotherapy, antibodies, or even radiation afterwards.
The idea is a response-adapted trial in early HER2-positive breast cancer that gives trastuzumab deruxtecan alone before surgery and, for patients who reach a pathological complete response, drops everything else: no further chemotherapy, antibodies alone or observation only. A pathological complete response predicts near-cure, PHERGain proved imaging-adapted omission is feasible, and T-DXd's complete-response rate approaches that of the best chemotherapy regimens. DESTINY-Breast11, where neoadjuvant T-DXd was followed by THP, and DESTINY-Breast05 bracket the curative setting. The test would be a single-arm study then randomised de-escalation, with PET and ctDNA as early response markers and lung toxicity as the safety endpoint.
One of the most cited trial reports Europe PMC returns for Trastuzumab in HER2-positive breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Trastuzumab in HER2-positive breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
This is the paper Europe PMC returns for registry id NCT00045032 with the most citations, so it is the natural first reading for anyone following the HERA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares PHERGain, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Pathologic complete response (pCR), Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Pathologic complete response (pCR), Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, Trastuzumab, HER2-positive breast cancer.
Shares PHERGain, Pertuzumab, Trastuzumab deruxtecan, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares DESTINY-Breast11, DESTINY-Breast05, PHERGain, Pertuzumab.